patent expirations news from FiercePharma
News
Silver lining to Big Pharma's cloud?
Some people see the Big Pharma glass as half-full instead of the alternative. In an investor's-eye look at the industry, Kiplinger ticks off the usual criticisms: patent expirations, tough generics Read more...
Safety questions on Fosamax, Actos, et al.
It must be tough for pharma execs to open a newspaper these days. If reporters aren't going on about Read more...
Lundbeck poaches CEO from Wyeth ranks
Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president Read more...
Under pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
SPOTLIGHT: The top five layoffs of 2007
2007 has been a rough year for a number of the pharmaceutical and biotech industry's biggest players. Concerns about patent expirations, falling sales due to drug safety concerns, redundancy from Read more...
Moody's downgrades pharma industry
As if Big Pharma didn't have enough challenges. Moody's Investors Services has downgraded the entire industry's credit rating, cutting its 12-month outlook to "Negative" from Read more...
Pfizer, Wyeth merger bad idea?
Fortune writer John Simons opines that a rumored merger of Pfizer and Wyeth would be all wrong for both companies. In his Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight